Dexamethasone Sodium Phospha · #13 of 35 active shortages by FDA posting duration
Brand: DEXAMETHASONE SODIUM PHOSPHATE
FDA lists Dexamethasone Sodium Phospha as Active Shortage (Mylan Institutional, a Viatris Company).
Availability on file: Available
Dexamethasone Sodium Phosphate Injection: Active Shortage
Available 16 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Dexamethasone Sodium Phosphate Injection
- Manufacturer
- Mylan Institutional, a Viatris Company
- Dosage Form
- Injection
- Presentation
- Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)
- Package NDC
- 67457-420-10
Status & Timeline
- Status
- Active Shortage
- Availability
- Available
- First Reported
- Feb 8, 2019
- Last Updated
- Mar 18, 2026
- Therapeutic Category
- Dermatology, Endocrinology/Metabolism, Gastroenterology, Hematology, Neurology, Oncology, Ophthalmology, Other, Pulmonary/Allergy, Rheumatology
Row fields from the FDA Drug Shortages database via openFDA.
Full Drug Profile
dexamethasone
Side effects, interactions, warnings & more
Nearby, Other Dexamethasone Shortage Records
Dexamethasone Sodium Phosphate Injection
Somerset Therapeutics, LLC
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Eugia US LLC
Injection
Dexamethasone Sodium Phosphate Injection
Mylan Institutional, a Viatris Company
Injection
Dexamethasone Sodium Phosphate Injection
Fresenius Kabi USA, LLC
Injection